Temozolomide News and Research

RSS

The risk of adverse reactions when herbal medications are taken with cancer drugs

A new study discusses phytovigilance initiatives based on the real-world use of herbal drugs in cancer along with conventional chemotherapy.

24 Aug 2022

New glioma drug may represent a paradigm for designing therapeutics exploiting specific DNA repair

A new class of glioma drugs exploits tumors that lack the DNA repair enzyme MGMT; the drugs lead to the generation of cytotoxic DNA and selectively kill tumor cells without the risk of resistance, researchers report.

29 Jul 2022

Repurposing an antipsychotic drug to treat various types of cancer

To treat some of the psychosis issues associated with Parkinson's disease, physicians often prescribe pimavanserin, an antipsychotic drug that acts within the brain to prevent hallucinations and delusions.

28 Jul 2022

Researchers identify biomarkers that could be targets for novel drugs to treat glioblastoma

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing hope for a cancer that is highly lethal.

22 Jun 2022

Infiltrating gliomas are shaped by genetic evolution and microenvironment, finds study

Researchers have discovered that infiltrating gliomas, a common brain and spinal cord tumor, are shaped by their genetic evolution and microenvironment, a finding that could lead to more targeted treatments.

9 Jun 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health's Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone.

6 Jun 2022

Novel photonic technology could enable fluorescent sensors to track molecules deep inside the body

Fluorescent sensors, which can be used to label and image a wide variety of molecules, offer a unique glimpse inside living cells.

30 May 2022

Treatment with Tumor Treating Fields triggers downstream anti-tumor cell response, study finds

Novocure announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response that may be effectively used together with existing immunotherapy approaches in the treatment of solid tumors, with limited systemic toxicity.

25 Feb 2022

Treatment with immune-boosting protein and radiation improves survival in mice with glioblastoma

Glioblastoma, an aggressive cancer in the brain or spinal cord, has proven stubbornly resistant to newer immunotherapies. And radiation and chemotherapy, the standard treatment for glioblastoma, result in fewer than 10% of patients surviving longer than five years after diagnosis.

19 Jan 2022

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.

5 Jan 2022

Scientists develop new approach to combat treatment-resistant melanoma

Researchers from the Centenary Institute have developed a new approach to fighting melanomas that fail to respond – or are resistant – to standard treatments. The deadliest form of skin cancer, melanoma is responsible for more than 1,700 deaths each year in Australia.

30 Oct 2021

Researchers develop new method to track the development of cancer cells

Changes in individual cancer cells over time may explain why brain tumours develop so differently, and why some cancer cells are resistant to certain treatments.

20 Sep 2021

Two studies on gastrointestinal stroma tumors describe advances that may lead to new treatments

Gastrointestinal stroma tumors (GIST) are cancers that start in specialized nerve cells found in the digestive system, from the esophagus and stomach to the intestines and rectum.

25 Aug 2021

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.

18 Jun 2021

Giving chemotherapy in the morning can extend survival of glioblastoma patients

An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years.

31 Mar 2021

Study: Reduced activity of specific enzyme leads to much higher cancer rates

In the past few years, several medications have been found to be contaminated with NDMA, a probable carcinogen. This chemical, which has also been found at Superfund sites and in some cases has spread to drinking water supplies, causes DNA damage that can lead to cancer.

17 Mar 2021

Three projects from University of Colorado Cancer Center receive grants for brain tumor research

Three projects from University of Colorado Cancer Center researchers have received grants from the Denver-based Michele Plachy-Rubin Fund for Pilot Grants in Brain Cancer Research. Receiving $40,000 each to fund their work around brain cancer are Sujatha Venkataraman, PhD; and the teams of Philip Reigan, PhD, and Michael Graner, PhD; and Natalie Serkova, PhD, and Nicholas Foreman, MD, MBChB.

10 Mar 2021

New glioma-targeted nano-therapeutic offers a potential treatment for glioblastomas

With a survival rate of only five years, the most common and aggressive form of primary brain tumor, glioblastoma multiforme, is notoriously hard to treat using current regimens that rely on surgery, radiation, chemotherapy, and their combinations.

24 Feb 2021

Mice study suggests novel approach to treat a type of common glioma

Gliomas are common brain tumors that comprise about one third of all cancers of the nervous system. In a study funded by the National Institutes of Health, researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas--a type of slow-growing glioma--and found tumor regression in 60 percent of the mice treated.

16 Feb 2021

Scientists avert drug resistance in subtype of brain tumors

In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.

11 Feb 2021